

Contents

| | |
|--|------------|
| 1 Systemic Therapy for Ovarian Cancer, Current Treatment, Recent Advances, and Unmet Needs | 1 |
| Susana Banerjee, Michael A. Bookman, and Martin Gore | |
| 2 Discovery of Novel Targets | 35 |
| John Farley and Michael J. Birrer | |
| 3 Novel Anti-angiogenic Therapies in Ovarian Cancer | 51 |
| Jurjees Hasan and Gordon Jayson | |
| 4 Targeting the AKT Pathway in Ovarian Cancer | 73 |
| Euan A. Stronach, Azadeh Cheraghchi-Bashi, Michelle Chen, and Hani Gabra | |
| 5 Inhibition of the Src Oncogene: Therapeutic Potential in Ovarian Carcinoma | 95 |
| Liz Y. Han and Anil K. Sood | |
| 6 Tumour-Specific Synthetic Lethality: Targeting <i>BRCA</i> Dysfunction in Ovarian Cancer | 109 |
| Timothy A. Yap, Stan Kaye, Alan Ashworth, and Andrew Tutt | |
| 7 Targeting Inflammatory Pathways in Epithelial Ovarian Cancer . | 133 |
| Jermaine Coward and Frances Balkwill | |
| 8 Epithelial-to-Mesenchymal Transition and Cellular Membrane Receptors in Ovarian Cancer: Moving Forward in the Era of Molecularly Targeted Therapy | 165 |
| Lainie P. Martin, Julia J. Perkins, and Russell J. Schilder | |
| 9 Epigenetic Therapies | 189 |
| Robert Brown, Nadine Chapman-Rothe, and Ros Glasspool | |
| 10 Ovarian Cancer Immunology and Immunotherapy | 203 |
| Sadaf Ghaem-Maghani and Martin Gore | |
| 11 Ovarian Cancer Progenitor/Stem Cells: Therapeutic Potential . . | 223 |
| Susan K. Murphy and Andrew Berchuck | |

| | |
|---|-----|
| 12 Potential for α-Folate Receptor-Targeted Treatment for Ovarian Cancer | 245 |
| Chau H.M. Ng and Ann L. Jackman | |
| 13 New Insights into Tubulin Binders | 259 |
| Carles Escriu and James D. Brenton | |
| Index | 279 |



<http://www.springer.com/978-1-4419-7215-6>

Emerging Therapeutic Targets in Ovarian Cancer

Kaye, S.; Brown, R.; Gabra, H.; Gore, M.E. (Eds.)

2011, XIII, 291 p., Hardcover

ISBN: 978-1-4419-7215-6